Zhejiang Taimei Medical Technology. 

HK$5.67
0
+HK$0.17+3% Friday 08:08

統計

當日最高
5.7
當日最低
5.46
52週高點
7.5
52週低點
3.61
成交量
503,800
平均成交量
945,309
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

財報

28Aug預期
Q2 2025
Q4 2025
下一步
-0.04
0.29
0.62
0.96
預期EPS
不適用
實際EPS
不適用

財務

-39.15%利潤率
未盈利
2021
2022
2023
2024
589.25M營收
-230.7M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.
Show more...
執行長
Wan Yunyun
員工
681
國家
中國
ISIN
CNE100006M66
WKN
000A40QVG

上市

0 Comments

分享你的想法

FAQ

Zhejiang Taimei Medical Technology. 今天的股價是多少?
2576.HK 目前價格為 HK$5.67 HKD,過去 24 小時上漲了 +3%。在圖表上更密切關注 Zhejiang Taimei Medical Technology. 股價表現。
Zhejiang Taimei Medical Technology. 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 Hong Kong Exchange 交易所,Zhejiang Taimei Medical Technology. 的股票以代號 2576.HK 進行交易。
Zhejiang Taimei Medical Technology. 下一次財報日期是什麼時候?
Zhejiang Taimei Medical Technology. 將於 August 28, 2026 公布下一次財報。
Zhejiang Taimei Medical Technology. 去年的營收是多少?
Zhejiang Taimei Medical Technology. 去年的營收為 589.25MHKD。
Zhejiang Taimei Medical Technology. 去年的淨利是多少?
2576.HK 去年的淨收益為 -230.7MHKD。
Zhejiang Taimei Medical Technology. 有多少名員工?
截至 August 15, 2026,公司共有 681 名員工。
Zhejiang Taimei Medical Technology. 位於哪個產業?
Zhejiang Taimei Medical Technology.從事於Technology產業。
Zhejiang Taimei Medical Technology. 何時完成拆股?
Zhejiang Taimei Medical Technology. 最近沒有進行任何拆股。
Zhejiang Taimei Medical Technology. 的總部在哪裡?
Zhejiang Taimei Medical Technology. 的總部位於 中國 的 Jiaxing。